InvivoSciences

Executive Summary

InvivoSciences (IVS) is a precision medicine company pioneering patient-derived 3D micro-tissue technology for drug development. Based in Madison, Wisconsin, IVS specializes in cardiovascular and drug delivery applications, leveraging an automated, scalable platform that integrates gene editing, tissue engineering, and AI-driven phenotyping. Their core offering—functional 3D engineered micro-human heart tissues—enables more predictive preclinical testing, potentially reducing late-stage drug failures. Founded in 2008, the company is currently at a pre-clinical stage and privately held. While specific funding details are undisclosed, IVS's focus on addressing the high unmet need in cardiovascular drug development positions it as an innovative player in the precision medicine space. The platform's ability to use patient-derived cells and gene-edited samples could offer significant advantages over traditional 2D assays and animal models, aligning with the FDA's push for more human-relevant testing methods. However, as a pre-clinical company, IVS faces typical risks around validation, scalability, and commercialization. The conviction score reflects cautious optimism given the technology's potential but limited public data on clinical progress.

Upcoming Catalysts (preview)

• Q2 2026Announcement of pharmaceutical partnership for cardiovascular drug testing40% success
• Q3 2026Publication of preclinical validation data in peer-reviewed journal60% success
• TBDSeries A funding round or grant award to scale platform50% success